Durable responses to long-term selumetinib in Chinese pediatric NF1 patients with inoperable plexiform neurofibromas
BackgroundThis study provides the first long-term efficacy and safety data of selumetinib in Chinese pediatric patients with inoperable symptomatic plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1).MethodsIn this single-center Phase I clinical trial(NCT04590235), we enrolle...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2026-06-01
|
| Edice: | Frontiers in Pharmacology |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1855171/full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|